Scribe Therapeutics to Participate in Upcoming Investor Conferences in May and June 2023

ALAMEDA, Calif.--(BUSINESS WIRE)-- Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that the Company will participate in the following upcoming investor conferences in May and June:

• SVB Securities Biopharma Private Company Connect: Members of management will be available for virtual one-on-one meetings on Wednesday, May 24, 2023 and Thursday, May 25, 2023.
• Stifel 2023 Tailoring Genes: Genetic Medicines Day: Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present a virtual corporate overview on Tuesday, May 30, 2023 at 12:05 p.m. ET.
• Jefferies Healthcare Conference: Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present a corporate overview on Friday, June 9, 2023 at 8:00 a.m. ET in New York, NY. Members of management will also be available for one-on-one meetings.

About Scribe Therapeutics

Scribe Therapeutics is revolutionizing the development of optimized genetic medicines that have the potential to durably treat disease at scale. Our CRISPR by Design™ approach engineers bacterial immune systems into a premier suite of genome editing tools built for unique molecular advantages in activity, specificity and deliverability that translate into safer and more effective genetic therapies. Co-founded by Nobel Prize winner Jennifer Doudna and backed by leading life sciences investors, Scribe is engineering the future of genetic medicine. To learn more, visit www.scribetx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230522005221/en/